Australien - engelska - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

USA - engelska - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g;   - powder for oral solution - 0.64 mg/g - active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g   excipient: aspartame

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - citric acid 12.77 mg/g; macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w); potassium chloride 10.55 mg/g; sodium chloride 37.33 mg/g;  ; sodium sulfate 80.62 mg/g; citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g - combination - active: citric acid 12.77 mg/g macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w) potassium chloride 10.55 mg/g sodium chloride 37.33 mg/g   sodium sulfate 80.62 mg/g excipient: ascorbic acid aspartame lemon flavour ql58817 active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g excipient: aspartame - indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination

Australien - engelska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Australien - engelska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Australien - engelska - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - beta vulgaris, quantity: 10 mg; heavy magnesium oxide, quantity: 165.84 mg (equivalent: magnesium, qty 100 mg); magnesium citrate, quantity: 156.25 mg (equivalent: magnesium, qty 25 mg); raphanus sativus, quantity: 1 mg (equivalent: raphanus sativus, qty 2 mg); brassica oleracea var. viridis, quantity: 10 mg; brassica oleracea var. viridis, quantity: 2 mg (equivalent: brassica oleracea var. viridis, qty 4 mg); brassica oleracea var. italica, quantity: 2 mg (equivalent: brassica oleracea var. italica, qty 4 - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium carbonate; croscarmellose sodium; stearic acid; purified water; silicon dioxide; glycerol; hypromellose - maintain/support energy levels ; maintain/support general health and wellbeing ; maintain/support heart health ; maintain/support muscle health ; maintain/support muscle function

USA - engelska - NLM (National Library of Medicine)

medical purchasing solutions, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Israel - engelska - Ministry of Health

teva israel ltd - sodium chloride - solution for infusion - sodium chloride 0.45 %w/v - sodium chloride - supply of water and electrolytes

USA - engelska - NLM (National Library of Medicine)

medical purchasing solutions, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.